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ABSTRACT
Airway remodeling in asthma has been recognized as structural changes of airways such as smooth muscle
hypertrophy (an increase in size of airway smooth muscle cells) and hyperplasia (an increase in the number of
airway smooth muscle cells), thickening and fibrosis of sub-epithelial basement membrane, hypertrophy of
bronchial glands, goblet cell hyperplasia, and thickening of airway epithelium. In these pathological changes,
airway smooth muscle remodeling has been recognized as one of the most important factors related to in vitro
and in vitro airway responsiveness and the severity of asthma. Both hypertrophy and hyperplasia have been
shown in asthmatic airways by morphometrical analyses, although there is a wide variation in the contribution
of each mechanism in each patient. Such changes could also be recognized as a phenotypic modulation of air-
way smooth muscle. On the background of airway smooth muscle remodeling, the existence of several contrib-
uting factors, such as inflammatory mediators, growth factors, cytokines, extra-cellular matrix proteins, and ge-
netic factors have been suggested. On the other hand, recent studies revealed that airway smooth muscle
could also be a source of inflammatory mediators promoting airway inflammation. In this article, the recent un-
derstanding in the mechanisms of airway smooth muscle remodeling in asthma, its relations to airway inflam-
mation and airway physiology, and possible usefulness of early intervention with inhaled glucocorticoids have
been discussed.
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INTRODUCTION
Asthma is a syndrome characterized by the presence
of two physiological characteristics, reversible airflow
limitation and airway hyperresponsiveness. However,
recent advance in asthma research revealed the im-
portance of airway inflammation existed behind these
physiological characteristics. According to such pro-
gress in the concept of asthma, the strategies of the
treatment have changed dramatically, and the impor-
tance of anti-inflammatory therapy with inhaled gluco-
corticoids has been recognized . Such concept has
been reflected to the guidelines for asthma diagnosis
and management including Japanese Guideline for
Asthma.1,2 The pronounced improvement in asthma
control and quality of life of the patients, and a dra-
matic reduction in the number of emergency room
visit and asthma death have been achieved. In these
situations , concerns of the pulmonary physicians
have been focused more on the patients with severe
intractable asthma. These patients have continuous
symptoms, irreversible airflow limitation, and resis-
tance to anti- inflammatory treatment with inhaled
glucocorticoids . Airway remodeling , recognized as
structural changes of airways produced by continu-
ous airway inflammation, is speculated to be one of
the most important causes for such severe intractable
asthma. In this article, the recent understanding in
the mechanisms of airway smooth muscle remodel-
ing , and its relations to airway inflammation and
physiology have been discussed.
LONG-TERM OUTCOME OF AIRWAY FUNC-
TION IN ASTHMA
In several studies , long-term outcomes of airway
function in patients with asthma have been studied
and the accelerated decline in forced expiratory vol-
ume in one second (FEV1) has been demonstrated.3-5
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Large scale epidemiological study by Lange and asso-
ciates revealed that the annual decline in FEV1 in
asthma and non-asthma were 38 mlyear and 22 ml
year, respectively, and asthmatics had additional 16
mlyear over-decline in FEV1.5 Similar enhanced an-
nual decline in FEV1 was also observed in relatively
large-scale surveys, such as Busselton Health Sur-
veys reported by James and associates and the sur-
vey by Apostol and associates.3,4 Such accelerated de-
cline is also reported for the subjects with airway hy-
perresponsiveness by Rijcken and associates . 6 The
subjects with airway hyperresponsiveness were re-
vealed to have additional 12 mlyear over-decline in
FEV1 compared to those without airway hyperrespon-
siveness. Several studies including ours also demon-
strated that, in asthmatic patients, there is a signifi-
cant negative correlation between the duration of
their disease and % predicted FEV1 measured during
stable phase or after inhalation of bronchodilators ,
but no significant correlation could be observed be-
tween % predicted FEV1 and the age of the patients.7
These finding suggest that the events continuing in
asthmatic airways may promote their airflow limita-
tion irreversible, and become critical factors for se-
vere and intractable asthma.
AIRWAY SMOOTH MUSCLE REMODELING
IN ASTHMA
Pathologists have long recognized that there are sig-
nificant pathological changes in asthmatic airways ,
such as airway smooth muscle hyperplasia and hy-
pertrophy , thickening and fibrosis of sub-epithelial
basement membrane , hypertrophy of bronchial
glands, goblet cell hyperplasia, and thickening of air-
way epithelium. In these pathological changes, air-
way smooth muscle remodeling has been recognized
as one of the most important factors related to in vitro
airway responsiveness and the severity of asthma.
These changes have been reported not only in severe
asthmatics but also in mild and moderate asthmatics.
In our previous studies for autopsied or operated
lungs of the patients with asthma showed that the air-
way epithelial thickness was doubled and airway
smooth muscle thickness was tripled in asthmatics
when compared to controls.8 Such pathological altera-
tions were observed even in young or mild asthmatic
subjects. The recent study by Niimi and associates re-
vealed that even in patients with cough variant
asthma , possible early manifestation of bronchial
asthma, airway remodeling recognized as a thicken-
ing of airway wall by high-resolution computer to-
mography could be observed. 9 In addition, the ap-
pearance of airway remodeling has been confirmed
even in children with bronchial asthma.10 These find-
ings suggest that airway remodeling is a relatively
common phenomenon observed widely in patients
with asthma, and may have significant importance in
clinical outcome of the patients.
The most prominent pathological change of airway
smooth muscle in asthmatic is an increase in smooth
muscle mass. Such change could be induced by sev-
eral mechanisms. Hypertrophy (an increase in size of
airway smooth muscle cells) and hyperplasia (an in-
crease in the number of airway smooth muscle cells)
are well known mechanisms . However , there is a
wide variation in the contribution of each mechanism
in each patient. Ebina and associates preformed 3-D
morphometry of airway muscle cells on serial sec-
tions of autopsied lungs from 10 asthmatic patients.11
They are consisted with 5 cases of type I (thickened
muscles is found only in the central bronchi) and 5
cases of type II (thickened muscles is found over the
whole airway tree) asthmatic lungs as defined in their
earlier study.12 In type I asthmatics, smooth muscle
cell hyperplasia was observed in the larger bronchi
without hypertrophy. In contrast, in type II asthmat-
ics , smooth muscle cell hypertrophy was observed
over the whole airway and hyperplasia was mild and
localized only in the bronchi. It has not been clarified
whether these differences affect clinical features of
the patients . In addition, there are still debates in
whether there is an enhancement of smooth muscle
proliferation in asthmatic airways. This question is of
physiological importance since it might be related to
phenotypic modulation of airway smooth muscle.13-15
The relation between increase in airway smooth mus-
cle mass and the duration of asthma has also been
recognized. Bai and associates compared the size of
airway smooth muscle mass in autopsy specimen ob-
tained from young (17―23 yr) and relatively aged (40―
49 yr) subjects. Smooth muscle area in both asthma
groups was greater than that in age-matched control
subjects. But, in relatively old individuals it was 4-fold
increase, and in young individuals it was 2-fold in-
crease compared with age-matched controls . 16 The
increase in extra-cellular matrix proteins may also in-
crease airway smooth muscle mass.17,18 The increase
in connective tissue matrix could be observed both
within muscle bundles and around individual cells .
Additional interesting observation is the presence of
mast cells in asthmatic airway smooth muscle bun-
dles. Brightling and associates examined pathological
differences of airways between asthma and eosino-
phililc bronchitis, and observed substantially higher
number of tryptase-positive mast cells in the smooth
muscle bundles from asthmatic airways compared to
that from subjects with eosinophilic bronchitis.19 This
finding suggests that the infiltration of airway smooth
muscle by mast cells is associated with the disor-
dered airway functions found in asthma. In consecu-
tive study, they revealed that IL-4 and IL-13 may play
an important role in this mast cell-airway smooth
muscle interactions.20
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AIRWAY SMOOTH MUSCLE REMODELING
AND AIRWAY PHYSIOLOGY
IN VIVO AND IN VITRO AIRWAY RESPONSIVE-
NESS IN ASTHMA
Airway hyper-responsiveness is one of the major
characteristics of asthma. Clinically, it can be demon-
strated by measuring FEV1 or airway resistance after
inhalation of incremental dose of non-specific airway
smooth muscle constrictor , such as acetylcholine ,
methacholine, and histamine. It seems not difficult to
connect airway smooth muscle remodeling and air-
way hyperresponsiveness in asthma. The increased
airway wall area including smooth muscle mass may
directly cause excess airways narrowing of asthma.
James and associates showed this mechanism ele-
gantly using a computer model and real airway di-
mensional data obtained from asthmatic and control
airways . 10 The airway wall area in asthmatics is
greater than non-asthmatic airways, and the airway
smooth muscle shortening required to occlude the lu-
men was less in asthmatic than non-asthmatic air-
ways. An increased mass of airway smooth muscle
bundle, demonstrated as airway smooth muscle hy-
pertrophy or hyperplasia, may increase the force gen-
erated during airway contraction. In smooth muscle
hyperplasia , increased number of smooth muscle
cells may cause parallel increase in contractile fila-
ments. In hypertrophic smooth muscle, there might
be an increase in intracellular contractile filaments .
These could increase the smooth muscle force to
contract the airway and to reduce airway caliber.
However, there is a fair amount of debate whether
airway responses to inhaled smooth muscle constric-
tors in vivo is correlated with airway smooth muscle
responsiveness in vitro. In subjects without lung dis-
eases, no significant correlation is observed between
in vitro airway responsiveness and in vivo airway
smooth muscle responsiveness. 21-23 There are only
few studies in which enhanced contractile responses
of airway smooth muscle from asthmatics compared
to non-asthmatic airway smooth muscle was con-
firmed. De Jongste and associates examined the re-
sponses of isolated human airways obtained from a
single asthmatic patient and compared to the re-
sponses of airways from 10 non-asthmatic subjects in
vitro. Asthmatic bronchiolar strips exhibited in-
creased contractile responses to histamine , meth-
acholine and leukotriene-C4, and relaxed normally in
response to l-isoprenaline and forskolin.24 Bai and as-
sociates also examined in vitro responsiveness of tra-
cheal smooth muscle obtained from 10 asthmatics
and 34 non-asthmatic controls, and observed signifi-
cant increase in maximum contraction induced by
electrical field stimulation and contractile agonists ,
and also revealed disturbed relaxation responses to
isoproterenol and theophylline . 25 However , other
studies failed to show the difference in contractile re-
sponses of asthmatic airway smooth muscle. Cerrina
and associates examined correlation between excised
human airway smooth muscle responsiveness in vitro
and in vivo airway responsiveness to histamine in 19
subjects including 5 patients with asthma and 7 pa-
tients with COPD. Although they could not observe a
significant correlation between in vivo and in vitro re-
sponsiveness to histamine , there was a significant
negative correlation between in vivo histamine re-
sponsiveness to in vitro airway smooth muscle re-
sponsiveness to isoproterenol.26 Same trends, no cor-
relation in contractile characteristics but negative cor-
relation to relaxation responses, are also recognized
in other studies.27 To summarize the results of above
studies , it seems reasonable to estimate that asth-
matic airway smooth muscle has abnormalities in re-
laxation response rather than contractile response .
The reduced relaxation responses to isoproterenol
and theophylline seems to be important in relation to
increased plasticity of airway smooth muscle in asth-
matics.28 It is speculated that the increased plasticity
might be related to the lack of airway dilatation after
deep inspiration, the most prominent characteristics
of asthmatic airways.29
However, it is still possible to explain the lack of in
vivo and in vitro correlation in contractile responses
in other ways. First example is for the measurement
system itself . In above studies isometric tension
measurements were applied. The claim is that iso-
metric properties of airway smooth muscle relate to
the stiffness of the airway wall and its role in regulat-
ing resistance is minor. In this aspect, it may not be
able to show the difference in smooth muscle con-
tractility without applying isotonic length measure-
ments. Actually, Ma and associates demonstrated sta-
tistically significant increases in maximum shorten-
ing capacity and velocity of airway smooth muscle
cells from asthmatics compared those from normal
subjects . 30 Another possible explanation is an in-
crease in elastic lord of asthmatic airways . Airway
wall fibrosis, including sub-epithelial fibrosis and an
increase in matrix proteins in and around airway
smooth muscle, may act as an elastic overlord for air-
way smooth muscle to reduce airway caliber.10 This
phenomenon has been demonstrated to be true by
Niimi and associates. They measured the airway wall
thickness by high-resolution computer tomography
and in vivo methacholine airway responsiveness in
asthmatics. There are a significant negative correla-
tion between airway wall thickness and methacholine
airway responsiveness, suggesting that thickened fi-
brous airways are hard to be compressed.31
PHENOTYPIC MODULATION OF AIRWAY
SMOOTH MUSCLE
When considering in vivo airway hyperresponsive-
ness, it may also involve reversible phenotypic modu-
lation. Now, three smooth muscle phenotypes have
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been recognized : contractile , synthetic and hyper-
contractile phenotypes. Contractile cells , character-
ized by a high density of contractile proteins includ-
ing smooth muscle α-actin and myosin heavy chains
(MHC) and a few cytoskeletal proteins including non-
muscle- MHC and vimentin, are mitotically quiescent
and retain their ability to contract in response to spas-
mogens. Synthetic cells, with a low density of con-
tractile proteins and high fraction of cytoskeletal pro-
teins, are mitotically active and may lose their ability
to contract.32 These cells may have additional func-
tions such as production and release of pro-
inflammatory mediators and extra-cellular matrix ele-
ment described in later section . Hyper-contractile
cells are obtained by prolonged withdrawal of serum
from primary cultures of confluent canine tracheal
smooth muscle . 33 The content of smooth muscle
myosin light chain kinase in these cells are increased
30 fold, and they shorten faster and to a greater ex-
tent.33,34 Whether such phenotypic modulation hap-
pens during remodeling of airway smooth muscle in
asthma has not been clarified yet. However, our pre-
liminary data suggest possible existence of such phe-
notypic modulation. Immuno-histochemical staining
of airway smooth muscle with antibodies for different
MHC isoforms revealed that the expression of non-
muscle (embryonic) type of MHC isoform is signifi-
cantly enhanced in asthmatic airway smooth muscle
compared to control (unpublished data) . Woodruff
and associates reported that there is a proliferation of
smooth muscle in asthmatic airways, but they could
not observe the phenotypic modulation of smooth
muscle to hyper-contractile phenotype . 13 The exis-
tence of such phenotypic modulation may make
things more complicated, since the co-appearance of
synthetic as well as hyper-contractile phenotypes may
result the overall effect of increasing, decreasing, or
causing no change in airway smooth muscle contrac-
tility despite an increase in airway wall smooth mus-
cle content.
MECHANISMS OF AIRWAY SMOOTH MUS-
CLE REMODELING
GENETIC BACKGROUND OF AIRWAY REMOD-
ELING
Some pulmonary physicians may have recognized
that there is a large intra-individual variation of airway
remodeling in asthma. Recent work by Roth and as-
sociates revealed that there might be an intrinsic ab-
normality in asthmatic airway smooth muscle. They
demonstrated the enhanced proliferation of bronchial
smooth-muscle cells derived from subjects with
asthma and the failure of glucocorticoids to inhibit
proliferation of these cells in vitro, possibly explained
by a cell-type-specific absence of CEBPalpha.35 Re-
cently, final results of several large scale positional
cloning for asthma susceptibility genes have been re-
ported, and now we have 4 possible asthma suscepti-
bility genes.36-39 Interestingly, some of these genes
are not expressed in immune regulatory cells such as
lymphocytes but are expressed mainly in airway
structural cells such as airway smooth muscle, epi-
thelium, and fibroblast. One of which is ADAM33, a
family member of proteases known as the ADAM su-
perfamily.36 High-level expression of ADAM33 is ob-
served in airway smooth muscles and fibroblasts and
suggests possible roles in airway remodeling in pa-
tients with asthma. The ADAM33 levels in bronchoal-
veolar lavage fluid (BALF) were increased signifi-
cantly in patients with asthma, and they correlate in-
versely with the %predicted FEV1, suggesting their
relation to the asthma severity.40 Van Diemen and as-
sociates recently demonstrated in the general popula-
tion that polymorphisms in ADAM33 gene are associ-
ated with accelerated decline in FEV1. 41 Another
gene is a GPRA, which belongs to the G protein-
coupled receptor family (GPCRs). GPRA is also ex-
pressed mainly in airway epithelium and smooth
muscle, and is speculated to have some relation to
airway remodeling.39
AIRWAY INFLAMMATION AND AIRWAY
SMOOTH MUSCLE REMODELING
Recently, tight interaction between airway inflamma-
tion and airway remodeling has been recognized .
Many inflammatory mediators are increased in asth-
matic lung and some of them are inducers of airway
smooth muscle proliferation (Table 1). These media-
tors include growth factors, inflammatory mediators,
contractile agonists, cytokines, and extra-cellular ma-
trix proteins.42
For the growth factors, there has been a contro-
versy whether the expression of growth factors and
their receptors are enhanced in asthmatic airways. In
early studies , for platelet derived growth factor
(PDGF) an insulin like growth factor (IGF), their
over-expression or increased levels in BALF were not
observed in asthmatics . 43-45 In addition , although
there was an increased expression of PDGF-mRNA in
asthmatic airways, PDGF receptor protein expression
was not observed by immunohistochemical stain-
ing. 44 Increased PDGF-mRNA expression seemed
due to the effect of corticosteroid used in the asth-
matic patients.44 On the other hand, there is an en-
hanced expression of epidermal growth factor (EGF)
in asthmatic airways obtained by autopsy and lung re-
section . 8 At the same time , there is an over-
expression of EGF receptor on the epithelial cells ,
bronchial gland cells , and smooth muscle cells in
asthmatic airways.8 These findings were confirmed in
the biopsy specimen obtained from asthmatic pa-
tients by bronchoscopy.46 In addition to smooth mus-
cle proliferative activities, EGF has also been demon-
strated to have smooth muscle contractile activities.47
Recently , Holgate and associates proposed the hy-
pothesis that an abnormal interaction between airway
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Table 1 Major Inflammatory Mediators with Potential Smooth Muscle Proliferative Activity
CytokinesGrowth Factors
IL-1βepidermal growth factor (EGF)
IL-6insulin-like growth factors (IGF)
tumor necrosis factor-α (TNF-α)platelet-derived growth factor (PDGF)
Plasma- or Inflammatory Cel-derived Mediators,basic fibroblast growth factor (BFGF)
lysomal hydrolasesfibroblast growth factor-2 (FGF-2)
α-thrombinContractile Agonists
tryptasehistamine 
sphingosine 1-phosphateendothelin-1 (ET-1)
Extracelular Matrix (ECM) Proteinssubstance P (SP)
colagen I, II, V phenylephrine 
fibronectin serotonin (5HT)
tenascin thromboxane A2 (TXA2)
hyaluronan leukotriene D4 (LTD4)
versican 
epithelium and mesenchymal cells, called epithelial-
mesenchymal trophic unit ( EMTU) , mediated by
EGFR system might be an important mechanism of
airway remodeling observed in asthma . 46,48 Trans-
forming growth factor (TGF)-β, known as an growth
factor inducing cell differentiation and fibrosis, is also
increased in asthmatic airways.49 In addition, eosino-
phils, an major player of allergic airway inflammation,
have been shown to be a main source of TGF-β . 50
Goldsmith and associates suggested the relation of
TGF-β to smooth muscle hypertrophy . 51 TGF-β in-
creased cell size and total protein synthesis, expres-
sion of alpha-smooth muscle actin and smooth mus-
cle MHC, formation of actomyosin filaments, and cell
shortening to acetylcholine . 51 On the other hand ,
TGF-β itself or together with fibroblast growth factor
2 (FGF2) also reported to induced airway smooth
muscle hyperplasia or proliferation.52,53
As shown in Table 1, many inflammatory mediators
increased in asthmatic airways induce airway smooth
muscle proliferation in vitro. Classical mediators ,
such as histamine, thromboxane, and leukotriene are
potent airway smooth muscle constrictors and are po-
tential smooth muscle mitogens. Endothelin-1, a po-
tent smooth muscle mitogen, are increased in BALF
from steroid-naïve asthmatics and correlate well with
% predicted FEV1.54 Pro-inflammatory cytokines, such
as interluekin-1β, IL-6, and TNF-α are also increased
in asthmatic airways and have some evidence to en-
hance smooth muscle proliferation.55-57 Th2 cytokine
receptors, such as IL-4 and 13 receptors, are also ex-
pressed in airway smooth muscle cells, and IL-13 has
been revealed to interfere the reduction in cell stiff-
ness induced by isoproterenol.58
Another important aspect of interaction between
airway inflammation and airway smooth muscle is
that airway smooth muscle itself could be a source of
mediators of airway inflammation and remodeling .
Recent studies have revealed that airway smooth
muscle cells release several mediators including cy-
tokines (such as GM-CSF, IL-2, -5, -6, -11, -12, -13,
IFN-γ), chemokines (such as eotaxin, RANTES, IL-8,
MCP-1, -2, -3, TARC), growth factors (PDGF, IGF,
SCF, VEGF) and inflammatory mediators in the air-
ways (PGE2, PLA2) . 59,60 Therefore , airway smooth
muscle cells might be a source of mediators of airway
inflammation, and may modulate autocrine prolifera-
tive responses.
MECHANISMS OF SMOOTH MUSCLE PROLIF-
ERATION INDUCED BY INFLAMMATORY ME-
DIATORS
The main intracellular pathways of smooth muscle
proliferation by inflammatory mediators have been
summarized well in the recent review articles.32,42,61
Figure 1 shows the brief outline of such mechanisms
in airway smooth muscle . Mediators classified into
growth factors, such as PDGF, EGF and IGF, act via
growth factor receptors with intrinsic receptor tyro-
sine kinase (RTK) activity. Activation of RTK induces
p21ras activation and stimulates two parallel signaling
pathways, namely, the extracellular signal-regulated
kinase (ERK) or the phosphatidylinositol 3-kinase
(PI3K) pathways. ERK phosphorylates nuclear pro-
tein such as cyclin D1 to induce DNA synthesis and
cell proliferation. PI3K activation also induced phos-
phorylation of cylin D1 through activation of the S6 ri-
bosomal kinase (p70S6K), Rac1, and PKCζ. Inflamma-
tory mediators such as histamine , thrombaxane-A2
and leukortriene-D4 stimulate G protein-coupled re-
ceptors (GPCRs). Stimulation of GPCRs induces deg-
radation of PIP3 into diacylglycerol (DAG) and inosi-
tol triphosphate (IP3). DAG activates protein kinase
C (PKC), and IP3 induces the release of stored Ca++
from endoplasmic reticulum (ER). The two stimuli to-
gether induce cell proliferation. There is also an evi-
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Fig. 1 Schematic presentation of signal transduction mechanisms regulat-
ing airway smooth muscle cel proliferation through major three receptors 
systems (see text).
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dence of link between GPCRs and the activation of
p21ras in human airway smooth muscle.62 Cytokines
signal through cell surface glycoprotein receptors
that function as oligomeric complexes consisting of
typically two to four receptor chains coupled to Src
family non-receptor tyrosine kinase , and stimulate
p21ras pathway . Recent study reported by Krym-
skaya and associates indicated that Src is a key mole-
cule even in human airway smooth muscle prolifera-
tion and migration.63 In addition, other interactions
among these three major pathways are also recog-
nized.47,64,65
PREVENTION AND TREATMENT OF AIR-
WAY SMOOTH MUSCLE REMODELING IN
ASTHMA
Strategy to control airway smooth muscle remodeling
in asthma has been studied intensively. Recent in vi-
tro experiments revealed that glucocorticoids inhibit
some but not all growth factor induced proliferation
of airway smooth muscle.66 Glucocorticoids arrest hu-
man airway smooth muscle cells in the G1 phase.
They reduce thrombin-stimulated increases in cyclin
D1 and also attenuate phosphorylation of retinoblas-
toma protein , via a pathway either downstream or
parallel to the mitogen- activated protein kinase
(MAPK) pathway.66 However, they are not effective
to inhibit airway smooth muscle cell mitogenesis in
response to RTK-activating mitogens. 42 Another ac-
tion of glucocorticoids might be an inhibition of
chemokine and cytokine secretion induced by inflam-
matory mediators. In experimental model of asthma,
several studies have shown evidences that glucocorti-
coids may inhibit airway smooth muscle remodeling.
We have examined the effect of salbutamol and meth-
ylprednisolone (mPSL ) on airway remodeling in-
duced by continuous exposure of antigen to Brown-
Norway Rats. MPSL inhibited airway remodeling al-
most completely, however, mono-therapy with salbu-
tamol worsened airway responsiveness to meth-
acholine and also enhanced airway epithelial remod-
eling, such as goblet cell hyperplasia.67 These in vitro
and in vivo experimental results suggest possible
usefulness of glucocorticoids to regulate airway
smooth muscle remodeling in asthma.
The important question for pulmonary physicians
is whether airway smooth muscle remodeling ob-
served in asthmatic patients could be regulated by in-
haled gulcocorticoids . Haatela and associates have
done the double blind crossover study to examine the
effect of inhaled glucocorticoids (budsonide) and β2-
agonist on pulmonary function including peek expira-
tory flow rate (PEFR). In this study, they compared
the improvement of PEFR by budesonide between
the group in which budesonide was introduced in the
first line and the group in which budesonide was
used in the second line, meaning two years delay in
the treatment with inhaled glucocorticoids. The im-
provement of PEFR was significantly attenuated in
the subjects with two years delay in the treatment
with inhaled glucocortids.68 Selroose and associates
have examined the relation between the duration of
asthma symptom before the beginning of inhaled glu-
cocorticoids therapy and the degree of improvement
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in PEFR and FEV1.69 They clearly demonstrated the
negative correlation between the degree of pulmo-
nary functional improvement and the duration of
symptom before the induction of inhaled glucocorti-
coids. These studies suggest that early intervention
with inhaled glucocorticoids may be important to im-
prove pulmonary functions and to control airway re-
modeling in asthma. Recently, the first results of ran-
domized control trial to examine the effect of early in-
tervention with inhaled glucocorticoids on airway re-
modeling in adult asthmatics have been published.70
In this study, after 3 years of treatment, there is a sig-
nificant improvement in post-bronchodilator FEV1 in
adult asthmatics treated with inhaled glucocorticoids
compared to those without it. However, in children
with asthma, early interventions with inhaled gluco-
corticoids did not improve post-bronchodilator FEV1,
suggesting the lack of inhibitory effect on airway re-
modeling. Same negative result was obtained in the
previous large scale study by the Childhood Asthma
Management Program (CAMP) Research Group.71 In
children, airway caliber is getting larger during their
growth, and the effect of early intervention might be
observed as an attenuation of airway growth . This
shows a clear contrast to the adult airways in which
constant decline in the caliber is observed during ag-
ing. That might be a cause of the difference observed
between children and adults asthmatics in early inter-
vention studies.70,71
Anti-asthmatics drugs other than inhaled glucocor-
ticoids, such as leukotriene modifiers, theophylline,
and β2-agonist ( especially long-acting β-agonist ;
LABA) have not studied extensively yet. When con-
sidering the mechanisms of airway smooth muscle
proliferation, there seems to be a good reason to ex-
pect usefulness of these drugs on airway remodeling.
In experimental asthma model, there are a few stud-
ies demonstrated the suppression of airway remodel-
ing by leukotriene modifiers.72 Although such experi-
mental models seem to be useful as models of acute
allergic airway inflammation, there are fair amount of
debates whether these models could be applied for
more chronic airway inflammation observed in severe
intractable asthma. Further attempts to obtain higher
level of clinical evidence for the effectiveness of these
anti-asthmatic drugs on airway remodeling, and to de-
velop new strategies to prevent or reverse airway re-
modeling have been awaited.
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